Introduction
============

People with schizophrenia tend to have a shorter life expectancy than the general population, not only due to their high suicide rate, but also due to cardiovascular events.[@b1-ndt-9-1683],[@b2-ndt-9-1683] People with schizophrenia are more likely to have metabolic abnormalities, including obesity, glucose intolerance, hypertension, dyslipidemia, and metabolic syndrome than the general population.[@b2-ndt-9-1683],[@b3-ndt-9-1683] These cardiometabolic risk factors are attributable to atypical antipsychotic-related weight gain and an unhealthy lifestyle, including dietary abnormalities, sedentary behavior, and a high prevalence of smoking.[@b1-ndt-9-1683],[@b2-ndt-9-1683],[@b4-ndt-9-1683]--[@b7-ndt-9-1683]

Among the risk factors for metabolic syndrome in patients with schizophrenia, antipsychotic treatment and a longer duration of disease course are associated with a higher risk of developing metabolic syndrome;[@b8-ndt-9-1683]--[@b12-ndt-9-1683] however, drug-naïve individuals with first-episode psychosis are also reported to have metabolic abnormalities.[@b13-ndt-9-1683] Therefore, innate factors, such as genetic predisposition, may play a role in determining the risk of metabolic dysregulation in patients with schizophrenia, and many researchers have made an attempt to identify these genetic risk factors.[@b14-ndt-9-1683] Consequently, there is growing evidence that genetic factors are, at least in part, responsible for the metabolic abnormalities in patients with schizophrenia.[@b14-ndt-9-1683] To identify these genetic factors, previous studies have been focused on target genes implicated in the antipsychotic action of drugs and weight regulation,[@b14-ndt-9-1683] but identification of numerous novel susceptibility genes is now ongoing, and can provide a better understanding of these conditions.

The major components of metabolic syndrome are generally agreed to include central obesity, hypertension, dyslipidemia, and glucose intolerance or insulin resistance. Commonly used definitions for metabolic syndrome include the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) metabolic syndrome definition[@b15-ndt-9-1683] and the adapted NCEP ATP III (ATP III-A) definition.[@b16-ndt-9-1683] Because the small physique of Asians makes it difficult to use the same waist circumference criteria for those of European descent,[@b17-ndt-9-1683] modified criteria for waist circumference have been proposed for Asians in the ATP III-A definition.[@b18-ndt-9-1683] To be diagnosed with metabolic syndrome according to the ATP III-A definition for Asians, individuals should meet or receive treatment for at least three of the following five criteria: an abnormal waist circumference (males ≥90 cm, females ≥80 cm), elevated blood pressure (≥130/85 mmHg), a decreased high-density lipoprotein level (HDL; males \<40 mg/dL, females \<50 mg/dL), an elevated triglyceride level (≥150 mg/dL), and an elevated fasting glucose level (≥100 mg/dL).[@b18-ndt-9-1683]

Recently, there has been increasing interest in the role of free radicals and oxidative stress in the pathogenesis of obesity and metabolic syndrome in the general population.[@b19-ndt-9-1683]--[@b21-ndt-9-1683] Oxidative damage and inflammation are present at the onset of obesity.[@b20-ndt-9-1683] The harmful effects of free radicals, primarily reactive oxygen species, and/or reactive nitrogen species, have been implicated in the physiopathology of obesity, hypertension, endothelial dysfunction, and metabolic syndrome, suggesting that oxidative stress is a mechanism underlying the dysfunctional metabolism observed in obese subjects.[@b19-ndt-9-1683]--[@b21-ndt-9-1683] For example, smoking and obesity are associated with low HDL cholesterol levels,[@b22-ndt-9-1683] and oxidative stress modifies specific amino acids in apolipoprotein A-I, a major component of HDL, resulting in a decrease in large HDL particles, such as HDL2.[@b23-ndt-9-1683]

The glutathione *S*-transferase (GST) supergene family consists of phase 2 detoxifying enzymes and plays a crucial role in antioxidant defense mechanisms by detoxifying electrophilic xenobiotics and inactivating a variety of endogenous byproducts of oxidative stress.[@b24-ndt-9-1683]--[@b26-ndt-9-1683] The most extensively studied *GST* polymorphisms occur in two isozymes found in the cytosol, ie, mu *(GSTM1)* and theta *(GSTT1)*.[@b24-ndt-9-1683],[@b26-ndt-9-1683] The human *GSTM1* gene contains eight exons located at 1p13.3, and the most common polymorphism in *GSTM1* is a deletion of the whole gene ("null" genotype) that results in a lack of functional activity of the enzyme.[@b24-ndt-9-1683],[@b26-ndt-9-1683] The human *GSTT1* gene contains four exons located at 22q11.2, and a homozygous deletion in *GSTT1* ("null" genotype) has also been reported.[@b24-ndt-9-1683],[@b26-ndt-9-1683] These two common deletion polymorphisms of *GSTM1* and *GSTT1* are reported to be associated with an increased susceptibility to certain oxidative stress-related diseases.[@b24-ndt-9-1683],[@b26-ndt-9-1683]--[@b30-ndt-9-1683] Meanwhile, superoxide dismutase 2 (SOD2, also known as manganese superoxide dismutase) converts superoxide to hydrogen peroxide and molecular oxygen in the mitochondrial matrix, representing the first line of cellular defense against oxidative stress.[@b31-ndt-9-1683] The *SOD2* gene contains five exons and spans almost 20 kb located at 6p25. The T to C nucleotide polymorphism (rs4880, Val16Ala) has been identified in exon 2 of the human *SOD2* gene, and the Ala variant is more efficiently imported into the mitochondria than the Val variant.[@b32-ndt-9-1683] Several studies have revealed that this *SOD2* polymorphism is associated with cardiovascular and metabolic diseases in the general population.[@b28-ndt-9-1683],[@b29-ndt-9-1683],[@b33-ndt-9-1683]

An increase in systemic oxidative stress in patients with schizophrenia has been reported, which may be due to the pathophysiology of schizophrenia, the sequelae of the therapeutic drugs used to treat schizophrenia, and/or the high prevalence of smoking among such individuals.[@b34-ndt-9-1683]--[@b36-ndt-9-1683] Therefore, it is possible that the influence of the *GST* and *SOD2* polymorphisms on development of metabolic abnormalities is more pronounced in patients with schizophrenia, especially under high oxidative stress conditions (eg, smokers). However, only one group has investigated the association between *GST* polymorphisms and olanzapine-induced weight gain,[@b37-ndt-9-1683] and there are presently no data regarding the effects of *GST* polymorphisms in association with other patient characteristics on the development of metabolic abnormalities in patients with schizophrenia. Meanwhile, no study has been published regarding the relationship between *SOD2* polymorphisms and metabolic abnormalities in patients with schizophrenia.

The present study investigated the possible associations between the most common and potentially functional polymorphisms in three antioxidant enzyme genes, ie, *GSTM1*, *GSTT1*, and *SOD2*, and the risks of being overweight and having metabolic syndrome in Japanese patients with schizophrenia in comparison with the general population, while also paying careful attention to associations with other patient characteristics.

Materials and methods
=====================

Subjects
--------

A cross-sectional, case-control analysis was conducted in 154 Japanese patients with schizophrenia and 203 Japanese controls. The patients with schizophrenia were recruited from the participants of a previous study.[@b38-ndt-9-1683] All patients were diagnosed with schizophrenia based on Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM-IV-TR) criteria, and had been treated with antipsychotic medication for at least 3 months at Hirosaki University Hospital in Japan prior to enrollment in the study. The diagnoses of the patients were recorded from their medical charts. Exclusion criteria included psychosis due to general medical conditions, substance-related psychosis, and mood disorders with psychotic features. Age-matched and sex-matched controls were recruited from participants in a 2-day health screening program conducted at the Japanese Red Cross Kumamoto Hospital Health Care Center. This study was approved by the institutional review boards of the Faculty of Life Sciences, Kumamoto University, the Hirosaki University School of Medicine, and the Japanese Red Cross Kumamoto Hospital Health Care Center. Informed consent, including a statement regarding the privacy policy, was obtained in writing from each volunteer before entry into the study.

Clinical assessments
--------------------

The height and weight of the subjects were measured, and the body mass index (BMI) was calculated. Overweight was diagnosed as a BMI ≥25 kg/m^2^. Presence of the metabolic syndrome was assessed based on the definitions proposed by the NCEP ATP III for Asians.[@b18-ndt-9-1683] The waist circumference was measured at the umbilical level in a standing position, to the nearest 0.1 cm, by a technician in the morning. Trained technicians measured blood pressure using a standard mercury sphygmomanometer on the right arm of seated participants after a 5-minute rest. HDL cholesterol and triglyceride levels were measured using standard enzymatic methods with kits (MetaboLead HDL-C and Determiner L TG II, respectively) from Kyowa Medex Co, Ltd (Tokyo, Japan) with an automated analyzer (Labospect 008; Hitachi Ltd, Tokyo, Japan). Fasting blood glucose levels were also measured using a glucose oxidase-immobilized enzyme membrane-hydrogen peroxide electrode method with glucose analyzers (GA-1170 and GA-1171; Arkray, Inc, Kyoto, Japan). Information on the subjects' demographics (age, sex, smoking status) and medical history were obtained from their medical records and by face-to-face interviews with medical staff members using a structured questionnaire.

Genotyping
----------

Genomic DNA was extracted from whole blood using a DNA purification kit (Qiagen, Flexi Gene DNA kit; Hilden, Germany). Null genotypes of *GSTM1* and *GSTT1* were determined using polymerase chain reaction (PCR) amplification based on the presence or absence of a PCR amplification product according to the method of Watanabe et al,[@b39-ndt-9-1683] with minor modifications. Briefly, null genotyping of *GSTT1* and *GSTM1* was determined using agarose electrophoresis. The *GSTM1* and *GSTT1* genes were amplified via PCR in the same reaction mixture described herein containing specific primer sets for *GSTM1* and *GSTT1*. The primer sequences for *GSTM1* were 5′-GAACTCCCTGAAAAGCTAAAGC-3′ (forward primer) and 5′-GTTGGGCTCAAATATACG-GTGG-3′ (reverse primer), while those for *GSTT1* were 5′-TTCCTTACTGGTCCTCACATCTC-3′ (forward primer) and 5′-TCACCGGATCATGGCCAGCA-3′ (reverse primer), and those for β-globin as an internal control were 5′-CAACT-TCATCCACGTTCACC-3′ (forward primer) and 5′-GAA-GAGCCAAGGACAGGTAC-3′ (reverse primer). The PCR analysis was performed using 30 cycles of 30 seconds at 94°C (degeneration), 30 seconds at 60°C (annealing), and 30 seconds at 72°C (elongation). The amplified DNA fragments were electrophoresed in 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet illumination. When the PCR products exhibited 0.23-kb or 0.46-kb bands, they were designated as wild-type *GSTM1* or *GSTT1* genes, respectively, and when no amplified bands were observed, they were designated as the null genotype ([Figure 1](#f1-ndt-9-1683){ref-type="fig"}). *SOD2* c.47T\>C (Val16Ala, rs4880) was genotyped by real-time PCR with 5′-nuclease allele discrimination assays (Step One Plus Real-Time PCR system version 2.1; Applied Biosystems, Tokyo, Japan). Genotyping for rs4880 was done using commercially available assays (assay ID: C_8709053_10). The reagents were purchased from Applied Biosystems, and genotyping was performed according to the manufacturer's protocol. To ensure genotyping quality, we included DNA samples as internal controls, hidden samples of a known genotype, and negative controls (water). Regarding *GSTM1* and *GSTT1*, the genotypes were classified as follows: subjects with homozygous deleted alleles (ie, the "null" genotype) and others (ie, the "present" genotype). Regarding *SOD2* c.47T\>C (Val16Ala), the genotypes were classified into three groups: homozygous for the *SOD2* T allele (ie, the Val/Val genotype), heterozygous for the T and C alleles (ie, the Val/Ala genotype), and homozygous for the C allele (ie, the Ala/Ala genotype).

Statistical analysis
--------------------

The data are presented as the mean ± standard deviation or number (%) of subjects. All continuous variables were analyzed using the Student's *t*-test. Categorical variables were compared by Fisher's exact test. The strength of the association between each genotype and the risk of being overweight, and that of having metabolic syndrome and abnormalities for each component of the metabolic syndrome was measured as odds ratios (ORs) with 95% confidence intervals (CIs) in patients with schizophrenia and the age-matched and sex-matched controls. The ORs were calculated via a logistic regression analysis that included all of the genotypes, patient categorical factors (ie, sex, smoking status, treatment with or without atypical antipsychotics, or inpatient/outpatient status), interactions between genotypes, and those between the genotype and each patient's factors as fixed effects, and age as a random effect. The use of atypical antipsychotics with a particular propensity to induce weight gain, ie, clozapine, olanzapine, risperidone, quetiapine, or perospirone, was included as a fixed effect. A value of *P*\<0.05 was considered to be statistically significant. These statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software package for Windows (version 17.0; IBM Japan Ltd, Tokyo, Japan). The statistical power of the associations between the genotypes and the risk of metabolic abnormalities was also calculated at a significance (alpha) level of 0.05 (two-tailed) and the adequate effect size (eg, an OR of 2.0 or 3.0) based on the sample size of this study and the observed frequencies of the genotypes and metabolic abnormalities using the SPSS Sample Power software program (version 3.0; IBM Japan Ltd).

Results
=======

Study population
----------------

The demographic and clinical characteristics of the study population are shown in [Table 1](#t1-ndt-9-1683){ref-type="table"}. The mean (± standard deviation) age was 50.2±15.3 years and 52.4±9.0 years (*P*=0.124), and the number (%) of females was 74 (48.1%) and 86 (42.4%) in the patients with schizophrenia and controls, respectively (*P*=0.334). Patients with schizophrenia had significantly greater body weight and a higher BMI than controls (*P*=0.011 and *P*\<0.0001, respectively). A total of 72 (46.8%) and 49 (24.1%) patients with schizophrenia and controls, respectively, were overweight (*P*\<0.0001). The prevalence of metabolic syndrome was 34 (22.1%) and 15 (7.4%) in patients with schizophrenia and controls, respectively (*P*\<0.0001). Waist circumference, systolic/diastolic blood pressure, and triglyceride levels were all significantly higher in patients with schizophrenia than in controls (*P*=0.003, *P*\<0.0001, and *P*=0.029, respectively), whereas HDL cholesterol was lower in patients with schizophrenia (*P*\<0.0001). Fasting glucose levels tended to be higher in patients with schizophrenia, although the difference did not reach statistical significance (*P*=0.070). The number of smokers was significantly greater in patients with schizophrenia than in controls (*P*\<0.0001). A total of 112 (72.7%) patients with schizophrenia were receiving atypical antipsychotics. Among them, 64, 32, 20, nine, and four were being treated with risperidone, olanzapine, quetiapine, perospirone, and aripiprazole, respectively. None of the patients was being treated with clozapine. Seventy patients were being treated with typical antipsychotics, including haloperidol (n=29), levomepromazine (n=25), chlorpromazine (n=19), sulpiride (n=6), and bromperidol (n=5). The patients had all been treated with either a single agent or a combination of these atypical and/or typical antipsychotic agents for at least 3 months prior to the analysis.

Allele and genotype frequencies in patients with schizophrenia and controls
---------------------------------------------------------------------------

The numbers (%) of patients with the *GSTM1* null genotype were 77 (50.0%) and 99 (48.8%) in the group with schizophrenia and the control group, respectively; those of the *GSTT1* null genotype were 68 (44.2%) and 99 (48.8%), respectively. The frequency (%) of the *GSTM1/GSTT1* double null genotype was 40 (26.0%) and 45 (22.2%) in patients with schizophrenia and controls, respectively. The allele frequencies of the *SOD2* Val16Ala polymorphism were 14.3% and 13.3% in patients with schizophrenia and controls, respectively. The numbers (%) of *SOD2* Ala/Ala and Val/Ala genotypes were three (1.9%) and 38 (24.7%), respectively, in patients with schizophrenia, and were four (2.0%) and 46 (22.3%), respectively, in controls. The observed *SOD2* genotype frequencies were consistent with the Hardy-Weinberg equilibrium (*P*\>0.05). The genotype frequencies of *GSTM1*, *GSTT1*, *GSTM1/GSTT1*, and *SOD2* in the patients with schizophrenia did not differ from those observed in the controls (*P*=0.831, *P*=0.394, *P*=0.164, and *P*=0.714, respectively) and were comparable with the frequencies observed in the general Japanese population.[@b40-ndt-9-1683],[@b41-ndt-9-1683] Since the frequency of the *SOD2* Ala/Ala genotype was too small in both groups, we combined the Ala/Ala and Ala/Val genotypes in the subsequent analyses. The mean age was significantly higher in subjects with the *GSTM1* null genotype than in those with the present genotype among the patients with schizophrenia ([Supplementary Table 1](#SD1-ndt-9-1683){ref-type="supplementary-material"}); whereas the patient age and number of females did not differ according to *GSTT1, SOD2*, and *GSTM1/GSTT1* genotypes ([Supplementary Tables 2](#SD2-ndt-9-1683){ref-type="supplementary-material"}--[5](#SD5-ndt-9-1683){ref-type="supplementary-material"}).

Association between genotypes and incidence of metabolic abnormalities in schizophrenic patients
------------------------------------------------------------------------------------------------

None of the *GSTM1*, *GSTT1*, and *SOD2* genotypes alone was associated with risk of overweight, metabolic syndrome, or abnormalities in each component of the metabolic syndrome in patients with schizophrenia ([Table 2](#t2-ndt-9-1683){ref-type="table"}). Since significant interactive effects of the *GSTM1* genotype and smoking status on the risks for being overweight and having an abnormal waist circumference (*P*=0.034 and *P*=0.018, respectively) were observed, we assessed the effects of *GSTM1* genotype on the risks of being overweight, having metabolic syndrome, and having abnormalities in each component of the metabolic syndrome separately in smokers and nonsmokers ([Table 3](#t3-ndt-9-1683){ref-type="table"}). Among the smokers, the incidences of being overweight and having decreased HDL cholesterol levels were significantly higher in those with the *GSTM1* null genotype than in those with the present genotype. Conversely, the incidence of having an abnormal waist circumference was significantly lower in nonsmokers with the *GSTM1* null genotype.

Given that an interactive effect of the *GSTM1* and *GSTT1* genotypes on the risk of having decreased HDL cholesterol was also observed (*P*=0.020), the relationships between the risk of metabolic abnormalities and the combinations of *GSTM1* and *GSTT1* genotypes were also analyzed ([Table 4](#t4-ndt-9-1683){ref-type="table"}). The risk of having a decreased HDL cholesterol level was significantly higher in patients with the *GSTM1* null/*GSTT1* present genotypes, but not in those with the *GSTM1* present/*GSTT1* null genotypes or *GSTM1* null/*GSTT1* null genotypes, compared with those with the *GSTM1* present/*GSTT1* present genotype. No other interactions between genotypes or between genotype and other patient-related factors (age, sex, smoking status, treatment with or without atypical antipsychotics, inpatient/outpatient status) were observed in the patients with schizophrenia.

When the magnitude of the effect size (ie, the OR value) was fixed at 2.0 and 3.0 in the 154 patients with schizophrenia, the statistical power of the associations between genotype and risk of metabolic abnormalities was 32%--56% and 56%--90%, respectively, based on the observed frequencies of the genotypes and metabolic abnormalities. Because we speculated that the influence of *GST* and *SOD2* polymorphisms on metabolic abnormalities would be more pronounced in patients under high oxidative stress conditions than in the remaining subjects, we also calculated the statistical power with a larger effect size (ie, an OR of 3.0 and 4.0) in the smokers with schizophrenia. When the OR was fixed at 3.0 and 4.0 in the 78 smokers with schizophrenia, the statistical power of the associations between genotype and risk of metabolic abnormalities was 55%--66% and 72%--82%, respectively. The respective percentages are shown in [Supplementary Table 6](#SD6-ndt-9-1683){ref-type="supplementary-material"}.

Association between genotype and incidence of metabolic abnormalities in age/sex-matched controls
-------------------------------------------------------------------------------------------------

None of the *GSTM1*, *GSTT1*, or *SOD2* genotypes examined was individually associated with the incidence of overweight, metabolic syndrome, or abnormalities in each component of the metabolic syndrome in controls ([Table 2](#t2-ndt-9-1683){ref-type="table"}). To compare the results in patients with schizophrenia, we assessed the effects of *GSTM1* genotype on the risks of being overweight, having a large waist circumference, and on the HDL cholesterol levels separately in smokers and nonsmokers, and also examined the effects of combinations of the *GSTM1* and *GSTT1* genotypes on the risk of decreased HDL cholesterol. The *GSTM1* null genotype was not associated with the incidence of overweight, an abnormal waist circumference, or a decreased HDL cholesterol level among smokers and nonsmokers ([Table 5](#t5-ndt-9-1683){ref-type="table"}). The risk of a decreased HDL cholesterol level was not significantly different in subjects with the *GSTM1* null/*GSTT1* present, *GSTM1* present/*GSTT1* null, and *GSTM1* null/*GSTT1* null genotypes compared with those with the *GSTM1* present/*GSTT1* present genotype ([Table 5](#t5-ndt-9-1683){ref-type="table"}).

Discussion
==========

The present study showed that none of the *GSTM1*, *GSTT1*, and *SOD2* genotypes examined were independent risk factors for metabolic abnormalities in patients with schizophrenia. On the other hand, when the possible associations between genotype and risk of metabolic abnormalities were analyzed, while also paying careful attention to the associations with other patient characteristics, the present study demonstrated the possible impact of the *GSTM1* null genotype on metabolic abnormalities in patients with schizophrenia.

In this study, we found that the risks of being overweight and having a decreased HDL cholesterol level were significantly higher in subjects with the *GSTM1* null genotype than in those with the present genotype among smokers with schizophrenia ([Table 3](#t3-ndt-9-1683){ref-type="table"}). The findings of the present study are in line with another recent study showing that the *GSTM1* null genotype was associated with a tendency toward a higher BMI and decreased HDL cholesterol in patients who underwent coronary angiography.[@b42-ndt-9-1683] Additionally, the interactive effects of current smoking and *GSTM1* null genotype on development of type 2 diabetes, nonalcoholic fatty liver disease, and several cancers have been reported in the general population.[@b27-ndt-9-1683],[@b30-ndt-9-1683],[@b43-ndt-9-1683],[@b44-ndt-9-1683] The findings of the present study also suggest that the *GSTM1* null genotype, in combination with current smoking, could be associated with the risks of being overweight and having decreased HDL cholesterol in patients with schizophrenia.

In this study, we found that the risk of an abnormal waist circumference was lower in nonsmoking schizophrenic subjects with the *GSTM1* null genotype ([Table 3](#t3-ndt-9-1683){ref-type="table"}). The *GSTM1* null genotype is reported to be one of the potential risk factors for various smoking-related diseases.[@b27-ndt-9-1683]--[@b30-ndt-9-1683],[@b43-ndt-9-1683] In this study, among smokers with schizophrenia, the risks of being overweight and having a decreased HDL cholesterol level were significantly higher in subjects with the *GSTM1* null genotype ([Table 3](#t3-ndt-9-1683){ref-type="table"}). It is thus possible that some nonsmoking patients harboring the high-risk *GSTM1* null genotype might have stopped smoking or made other lifestyle modifications, which may have led to the lower risk of abdominal obesity. In fact, the frequency of the *GSTM1* null genotype tended to be higher in nonsmokers than in smokers with schizophrenia (53.9% versus 46.2%; see [Supplementary Table 7](#SD7-ndt-9-1683){ref-type="supplementary-material"}). However, because we could not obtain information about these lifestyle-related factors, including past smoking status, from the patients in the present study, the association between the *GSTM1* null genotype and the lower risk of an abnormal waist circumference in nonsmokers with schizophrenia needs to be confirmed in a longitudinal study incorporating a collection of detailed lifestyle information.

The present study shows that the risk of decreased HDL cholesterol was significantly higher in subjects with the *GSTM1* null/*GSTT1* present genotypes, but not in those with the *GSTM1* present/*GSTT1* null and *GSTM1* null/*GSTT1* null genotypes, compared with the *GSTM1* present/*GSTT1* present genotypes ([Table 4](#t4-ndt-9-1683){ref-type="table"}). These findings suggest that the *GSTM1* null, rather than the *GSTT1* null, genotype might be associated with the risk of having decreased HDL cholesterol levels in patients with schizophrenia. The *GSTT1* null genotype, especially in combination with the *GSTM1* null genotype, has been reported to be associated with the risk of cardiovascular or metabolic disease in the general population.[@b27-ndt-9-1683]--[@b29-ndt-9-1683],[@b44-ndt-9-1683] The frequency of nonsmoking tended to be higher in subjects with the *GSTM1* null/*GSTT1* null genotypes (57.5%) compared with those having the other combinations (32.1%--53.1%) in the present study (see [Supplementary Table 4](#SD4-ndt-9-1683){ref-type="supplementary-material"}), which might be related to the lack of an association between the *GSTM1/GSTT1* double null genotypes and the metabolic abnormalities observed in this study. Nevertheless, larger studies are required to elucidate the influence of the *GSTT1* null genotype and/or combination with the *GSTM1* null genotype on the risk of metabolic abnormalities in patients with schizophrenia.

A previous study of 78 Korean patients with schizophrenia demonstrated that there were no differences in the null genotype distribution of *GSTM1* and *GSTT1* between subjects with a body weight gain ≥7% compared with subjects with a body weight gain \<7% after long-term olanzapine treatment.[@b37-ndt-9-1683] However, the level of lipid peroxidation appears to be significantly higher after treatment with typical antipsychotics,[@b45-ndt-9-1683] and a significant increase in lipid peroxidation was observed after long-term treatment with clozapine, ziprasidone, and risperidone, but not with olanzapine, in the rat brain.[@b46-ndt-9-1683] The patients in the present study were treated with olanzapine, as well as with other atypical and typical antipsychotics, and/or combinations of these agents, whereas patients were excluded if they took antipsychotics other than olanzapine in the Korean study.[@b37-ndt-9-1683] Therefore, we speculate that levels of systemic reactive oxygen species might have been higher in the patients included in the present study than in those in the Korean study, resulting in the significant effects of the *GSTM1* null genotype on the metabolic abnormalities in patients with schizophrenia observed in the present study.

SOD2 also plays crucial roles in antioxidant defense mechanisms.[@b31-ndt-9-1683] The Val16Ala polymorphism has been linked to cardiovascular disease and to type 2 diabetes and its complications in the general population, but studies so far have yielded conflicting results.[@b28-ndt-9-1683],[@b29-ndt-9-1683],[@b33-ndt-9-1683] In the present study, we did not find any significant associations between the *SOD2* genotype and the risks of being overweight and having metabolic syndrome in patients with schizophrenia or controls. Although further study is required to elucidate this relationship in a larger number of subjects, it is possible that the *SOD2* Val16Ala polymorphism as a risk factor by itself is not strong enough to demonstrate a significant association with metabolic abnormalities in patients with schizophrenia.

This investigation has some potential limitations. First, the power of the samples in the analyses ranging from 32% to 90% ([Supplementary Table 6](#SD6-ndt-9-1683){ref-type="supplementary-material"}) and the small number of subjects were major limitations. Therefore, the present study may not have had enough power to clarify whether *GSTM1*, *GSTT1*, and *SOD2* polymorphisms are independent risk factors for metabolic abnormalities in patients with schizophrenia, and a type 1 error cannot be excluded. Specifically, when effect size (ie, OR) is fixed at 2.0 with a statistical power of 0.80, a sample size of 322--540 patients would be needed to determine the effects of the *SOD2* genotype before any definitive conclusions can be drawn. Further, the prevalence of overweight and metabolic syndrome was low in the controls ([Table 1](#t1-ndt-9-1683){ref-type="table"}), which might have contributed to our results showing that none of the polymorphisms was associated with metabolic abnormalities in the controls. Second, this was a cross-sectional study that had only one assessment for metabolic abnormalities, and several potential covariates associated with overweight and metabolic syndrome could not be included, such as dietary habits, physical activity levels, past smoking status, duration of illness, and treatment and schizophrenic symptoms. Therefore, as in any study examining genotype-phenotype relationships, replication of the current findings is required.

Conclusion
==========

The results of the present study suggest that the *GSTM1* null genotype, in combination with smoking status or *GSTT1* genotype, may be associated with the risk of metabolic abnormalities in Japanese patients with schizophrenia. Although these results need to be confirmed in further investigations with larger samples, our findings provide new insight for continued work in this area.

Supplementary tables
====================

###### 

Demographic and clinical characteristics according to *GSTM1* genotype in patients with schizophrenia and controls

                                                                     Schizophrenia (n=154)   Controls (n=203)                                      
  ------------------------------------------------------------------ ----------------------- ------------------ ------- ------------- ------------ -------
  Number[b](#tfn21-ndt-9-1683){ref-type="table-fn"}                  77 (50.0%)              77 (50.0%)         --      104 (51.2%)   99 (48.8%)   --
  Age (years)                                                        47.5±14.8               52.9±15.4          0.027   52.6±9.2      52.1±8.8     0.701
  Male[c](#tfn22-ndt-9-1683){ref-type="table-fn"}                    41 (53.2%)              39 (50.6%)         0.872   58 (55.8%)    59 (59.6%)   0.670
  Smoker[c](#tfn22-ndt-9-1683){ref-type="table-fn"}                  42 (54.5%)              36 (46.8%)         0.420   22 (22.2%)    21 (20.2%)   0.735
  Height (cm)                                                        161.8±8.4               161.5±8.5          0.844   162.4±9.5     163.4±8.3    0.436
  Weight (kg)                                                        66.1±13.9               64.1±13.3          0.360   60.6±11.6     62.9±10.0    0.127
  BMI (kg/m^2^)                                                      25.1±4.2                24.4±4.0           0.297   22.9±3.3      23.5±3.1     0.136
  Overweight[c](#tfn22-ndt-9-1683){ref-type="table-fn"}              34 (44.2%)              38 (49.4%)         0.628   26 (25.0%)    23 (23.2%)   0.870
  Metabolic syndrome[c](#tfn22-ndt-9-1683){ref-type="table-fn"}      16 (20.8%)              18 (23.4%)         0.846   9 (8.7%)      6 (6.1%)     0.595
  Waist circumference (cm)                                           87.3±12.4               84.9±11.3          0.203   82.2±8.3      83.5±7.8     0.260
  Systolic blood pressure (mmHg)                                     123.0±14.5              128.8±17.9         0.027   116.6±16.8    117.7±15.7   0.642
  Diastolic blood pressure (mmHg)                                    75.9±10.4               77.7±13.4          0.345   71.4±11.1     74.4±10.8    0.056
  High-density lipoprotein (mg/dL)                                   53.9±15.1               50.3±13.9          0.122   65.2±16.4     65.9±18.2    0.768
  Triglycerides (mg/dL)                                              151.4±119.1             146.5±156.6        0.828   122.1±104.1   119.8±68.1   0.851
  Fasting blood glucose (mg/dL)                                      102.9±36.7              103.1±27.6         0.974   95.2±18.8     97.4±21.5    0.437
  Outpatients[c](#tfn22-ndt-9-1683){ref-type="table-fn"}             50 (64.9%)              43 (55.8%)         0.323   --            --           --
  Treatment with AAP(s)[c](#tfn22-ndt-9-1683){ref-type="table-fn"}   54 (70.1%)              58 (75.3%)         0.588   --            --           --

**Notes:** Data expressed as the mean ± standard deviation

*P*-values were determined by Student's *t*-test or Fisher's exact test

values in parentheses indicate percentages in patients with schizophrenia and controls, respectively

values in parentheses indicate percentages among the subjects with each genotype.

**Abbreviations:** AAP(s), atypical antipsychotics except for aripiprazole; BMI, body mass index; *GST*, glutathione *S*-transferase.

###### 

Demographic and clinical characteristics according to *GSTT1* genotype in patients with schizophrenia and controls

                                                                     Schizophrenia (n=154)   Controls (n=203)                                      
  ------------------------------------------------------------------ ----------------------- ------------------ ------- ------------- ------------ -------
  Number[b](#tfn26-ndt-9-1683){ref-type="table-fn"}                  86 (55.8%)              68 (44.2%)         --      104 (51.2%)   99 (48.8%)   --
  Age (years)                                                        50.1±15.0               50.4±15.7          0.904   51.6±9.4      53.1±8.5     0.233
  Male[c](#tfn27-ndt-9-1683){ref-type="table-fn"}                    46 (53.5%)              34 (50.0%)         0.746   64 (61.5%)    53 (53.5%)   0.259
  Smoker[c](#tfn27-ndt-9-1683){ref-type="table-fn"}                  42 (48.8%)              36 (52.9%)         0.630   26 (25.0%)    17 (17.2%)   0.229
  Height (cm)                                                        160.6±8.1               163.0±8.6          0.080   163.9±8.0     161.8±9.7    0.087
  Weight (kg)                                                        64.2±12.8               66.3±14.5          0.324   62.6±10.3     60.8±11.4    0.235
  BMI (kg/m^2^)                                                      24.8±4.1                24.8±4.0           0.969   23.2±2.9      23.1±3.4     0.852
  Overweight[c](#tfn27-ndt-9-1683){ref-type="table-fn"}              40 (46.5%)              32 (47.1%)         1.000   24 (23.1%)    25 (25.3%)   0.745
  Metabolic syndrome[c](#tfn27-ndt-9-1683){ref-type="table-fn"}      17 (19.8%)              17 (25.0%)         0.442   5 (4.8%)      10 (10.1%)   0.184
  Waist circumference (cm)                                           85.6±12.1               86.8±11.8          0.529   83.1±7.6      82.6±8.6     0.648
  Systolic blood pressure (mmHg)                                     125.0±16.9              127.1±16.0         0.447   117.5±16.5    116.8±16.0   0.775
  Diastolic blood pressure (mmHg)                                    75.6±10.9               78.3±13.2          0.157   73.3±11.3     72.4±10.7    0.531
  High-density lipoprotein (mg/dL)                                   53.1±16.1               50.9±12.5          0.335   64.1±16.7     67.1±17.7    0.215
  Triglycerides (mg/dL)                                              134.8±93.9              166.9±179.3        0.184   125.0±101.6   116.8±71.6   0.508
  Fasting blood glucose (mg/dL)                                      101.3±23.1              105.2±41.3         0.467   95.7±17.7     96.9±22.4    0.662
  Outpatients[c](#tfn27-ndt-9-1683){ref-type="table-fn"}             55 (64.0%)              38 (55.9%)         0.324   --            --           --
  Treatment with AAP(s)[c](#tfn27-ndt-9-1683){ref-type="table-fn"}   61 (70.9%)              51 (45.5%)         0.591   --            --           --

**Notes:** Data expressed as the mean ± standard deviation

*P*-values were determined by Student's *t*-test or Fisher's exact test

values in parentheses indicate percentages in patients with schizophrenia and controls, respectively

values in parentheses indicate the percentages among the subjects with each genotype.

**Abbreviations:** AAP(s), atypical antipsychotics except for aripiprazole; BMI, body mass index; *GST*, glutathione *S*-transferase.

###### 

Demographic and clinical characteristics according to *SOD2* genotype in patients with schizophrenia and controls

                                                                     Schizophrenia (n=154)   Controls (n=203)                                        
  ------------------------------------------------------------------ ----------------------- ------------------ ------- ------------- -------------- -------
  Number[b](#tfn31-ndt-9-1683){ref-type="table-fn"}                  113 (73.4%)             41 (26.6%)         --      153 (75.4%)   50 (24.6%)     --
  Age (years)                                                        49.5±15.2               52.2±15.6          0.334   52.4±9.0      52.3±8.8       0.993
  Male[c](#tfn32-ndt-9-1683){ref-type="table-fn"}                    59 (52.2%)              21 (51.2%)         1.000   88 (57.5%)    29 (58.0%)     1.000
  Smoker[c](#tfn32-ndt-9-1683){ref-type="table-fn"}                  57 (50.4%)              21 (51.2%)         1.000   34 (22.2%)    9 (18.0%)      0.690
  Height (cm)                                                        162.0±8.4               160.8±8.5          0.417   163.0±9.2     162.4±8.2      0.688
  Weight (kg)                                                        65.7±13.4               63.6±14.1          0.406   61.9± 11.1    61.2±10.3      0.711
  BMI (kg/m^2^)                                                      24.9±4.1                24.4±4.0           0.526   23.2±3.1      23.2±3.4       0.996
  Overweight[c](#tfn32-ndt-9-1683){ref-type="table-fn"}              55 (48.7%)              17 (41.5%)         0.469   34 (22.2%)    15 (30.0%)     0.261
  Metabolic syndrome[c](#tfn32-ndt-9-1683){ref-type="table-fn"}      24 (21.2%)              10 (24.4%)         0.666   11 (7.2%)     4 (8.0%)       0.765
  Waist circumference (cm)                                           86.7±11.6               84.8± 12.9         0.391   82.8±8.0      83.1 ±8.5      0.827
  Systolic blood pressure (mmHg)                                     124.6± 15.5             129.5±18.7         0.142   117.3±15.7    116.8±17.8     0.856
  Diastolic blood pressure (mmHg)                                    76.5±11.4               77.7± 13.5         0.573   72.9± 11.1    72.6± 10.9     0.858
  High-density lipoprotein (mg/dL)                                   51.3±14.0               54.4± 16.2         0.231   65.0±17.4     67.1 ±16.7     0.460
  Triglycerides (mg/dL)                                              150.7± 148.4            144.3±108.7        0.802   119.8±72.3    124.7± 125.8   0.732
  Fasting blood glucose (mg/dL)                                      102.6±31.2              104.2±35.7         0.780   96.9±21.0     94.4±17.2      0.447
  Outpatients[c](#tfn32-ndt-9-1683){ref-type="table-fn"}             69 (61.1%)              24 (58.5%)         0.853   --            --             --
  Treatment with AAP(s)[c](#tfn32-ndt-9-1683){ref-type="table-fn"}   84 (74.3%)              28 (68.3%)         0.540   --            --             --

**Notes:** Data expressed as the mean ± standard deviation;

*P*-values were determined by student's *t*-test or Fisher's exact test;

values in parentheses indicate percentages in patients with schizophrenia and controls, respectively;

values in parentheses indicate the percentages among the subjects with each genotype.

**Abbreviations:** AAP(s), atypical antipsychotics except for aripiprazole; BMi, body mass index; *SOD2*, superoxide dismutase.

###### 

Demographic and clinical characteristics according to the combination of *GSTM1* and *GSTT1* genotypes in the overall population of patients with schizophrenia

  *GSTM1* and *GSTT1* genotypes                                      *M1* present/*T1* present   *M1* null/*T1* present   *M1* present/*T1* null   *M1* null/*T1* null   *P[a](#tfn35-ndt-9-1683){ref-type="table-fn"}*
  ------------------------------------------------------------------ --------------------------- ------------------------ ------------------------ --------------------- ------------------------------------------------
  Number[b](#tfn36-ndt-9-1683){ref-type="table-fn"}                  49 (31.8%)                  37 (24.0%)               28 (18.2%)               40 (26.0%)            --
  Age (years)                                                        49.2±15.1                   51.3±15.1                44.6±13.9                54.4±15.7             0.064
  Male[c](#tfn37-ndt-9-1683){ref-type="table-fn"}                    28 (57.1%)                  18 (48.6%)               13 (46.4%)               21 (52.5%)            0.802
  Smokers[c](#tfn37-ndt-9-1683){ref-type="table-fn"}                 23 (46.9%)                  19 (51.4%)               19 (67.9%)               17 (42.5%)            0.203
  Height (cm)                                                        161.1±7.8                   160.0±8.6                163.1±9.4                163.0±8.2             0.332
  Weight (kg)                                                        64.4±13.1                   63.9±12.7                69.2±15.0                64.4±14.0             0.381
  BMI (kg/m^2^)                                                      24.7±4.1                    24.9±4.3                 25.8±4.2                 24.0±3.7              0.338
  Overweight[c](#tfn37-ndt-9-1683){ref-type="table-fn"}              20 (40.8%)                  20 (54.1%)               14 (50.0%)               18 (45.0%)            0.660
  Metabolic syndrome[c](#tfn37-ndt-9-1683){ref-type="table-fn"}      7 (14.3%)                   10 (27.0%)               9 (32.1%)                8 (20.0%)             0.252
  Waist circumference (cm)                                           85.5±12.3                   85.8±12.0                90.7±12.2                84.1±10.8             0.142
  Systolic blood pressure (mmHg)                                     123.2±16.3                  127.4±17.7               122.6±11.1               130.2±18.2            0.144
  Diastolic blood pressure (mmHg)                                    74.8±10.3                   76.6±11.6                77.8±10.4                78.8±14.9             0.463
  High-density lipoprotein (mg/dL)                                   56.0±15.8                   49.2±15.8                50.2±13.5                51.3±12.0             0.132
  Triglycerides (mg/dL)                                              128.8±75.7                  142.8±114.3              191.0±165.0              150.0±188.9           0.299
  Fasting glucose (mg/dL)                                            99.4±23.7                   103.9±22.4               109.1±52.3               102.4±31.9            0.652
  Outpatients[c](#tfn37-ndt-9-1683){ref-type="table-fn"}             31 (63.3%)                  24 (64.9%)               19 (67.9%)               19 (47.5%)            0.284
  Treatment with AAP(s)[c](#tfn37-ndt-9-1683){ref-type="table-fn"}   36 (73.5%)                  25 (67.6%)               18 (64.3%)               33 (82.5%)            0.308

**Notes:** Data expressed as the mean ± standard deviation

*P*-values were determined by analysis of variance or Fisher's exact test

values in parentheses indicate percentages in *GSTM1* present/*T1* present, *M1* null/*T1* present, *M1* present/*T1* null, *M1* null/*T1* null genotypes, respectively

values in parentheses indicate percentages among the subjects with each genotype.

**Abbreviations:** AAP(s), atypical antipsychotics except for aripiprazole; BMI, body mass index; *GST*, glutathione *S*-transferase.

###### 

Demographic and clinical characteristics according to the combination of *GSTM1* and *GSTT1* genotypes in the overall population of controls

  *GSTM1* and *GSTT1* genotypes                                   *M1* present/*T1* present   *M1* null/*T1* present   *M1* present/*T1* null   *M1* null/*T1* null   *P[a](#tfn40-ndt-9-1683){ref-type="table-fn"}*
  --------------------------------------------------------------- --------------------------- ------------------------ ------------------------ --------------------- ------------------------------------------------
  Number[b](#tfn41-ndt-9-1683){ref-type="table-fn"}               50 (24.6%)                  54 (26.6%)               54 (26.6%)               45 (22.2%)            --
  Age (years)                                                     51.8±9.2                    51.4±9.6                 53.3±9.2                 52.9±7.6              0.679
  Male[c](#tfn42-ndt-9-1683){ref-type="table-fn"}                 30 (60.0%)                  34 (63.0%)               28 (51.9%)               25 (55.6%)            0.676
  Smoker[c](#tfn42-ndt-9-1683){ref-type="table-fn"}               12 (24.0%)                  14 (25.9%)               9 (16.7%)                8 (17.8%)             0.618
  Height (cm)                                                     163.4±8.1                   164.4±8.0                161.4±10.6               162.2±8.7             0.333
  Weight (kg)                                                     62.4±10.1                   62.8±10.6                58.9±12.7                63.0±9.4              0.177
  BMI (kg/m^2^)                                                   23.3±3.1                    23.2±2.8                 22.4±3.4                 24.0±3.3              0.123
  Overweight[c](#tfn42-ndt-9-1683){ref-type="table-fn"}           13 (26.0%)                  11 (20.4%)               13 (24.1%)               12 (26.7%)            0.872
  Metabolic syndrome[c](#tfn42-ndt-9-1683){ref-type="table-fn"}   3 (6.0%)                    2 (3.7%)                 6 (11.1%)                4 (8.9%)              0.487
  Waist circumference (cm)                                        84.1±7.5                    82.2±7.6                 80.5±8.7                 85.1±7.9              0.023
  Systolic blood pressure (mmHg)                                  118.9±17.4                  116.2±15.7               114.6±16.1               119.6±15.6            0.371
  Diastolic blood pressure (mmHg)                                 73.2±11.6                   73.5±11.2                69.8±10.4                75.4±10.4             0.075
  High-density lipoprotein (mg/dL)                                63.0±16.8                   65.1±16.7                67.3±15.8                66.9±20.0             0.583
  Triglycerides (mg/dL)                                           134.9±129.4                 115.8±66.4               110.3±72.5               124.6±70.4            0.515
  Fasting glucose (mg/dL)                                         93.9±8.6                    97.4±23.2                96.5±24.7                97.5±19.6             0.790

**Notes:** Data expressed as the mean ± standard deviation.

*P*-values were determined by analysis of variance or Fisher's exact test

values in parentheses indicate percentages in *GSTM1* present/*T1* present, *M1* null/*T1* present, *M1* present/*T1* null, and *M1* null/*T1* null genotypes, respectively

values in parentheses indicate the percentages among subjects with each genotype.

**Abbreviations:** BMI, body mass index; *GST*, glutathione *S*-transferase.

###### 

Statistical power of associations between the genotypes and risk of metabolic abnormalities in patients with schizophrenia and smokers with schizophrenia at a significance (alpha) level of 0.05 (two-tailed) and adequate effect sizes (ie, odds ratios 2.0, 3.0, and 4.0) based on the sample size of the study and observed frequencies of the genotypes and metabolic abnormalities

                                 All patients with schizophrenia (n=154)   Smokers with schizophrenia (n=78)                                 
  ------------------------------ ----------------------------------------- ----------------------------------- ----- ----- ----- ----- ----- -----
  Overweight                     56%                                       90%                                 55%   90%   46%   83%   63%   81%
  MetS                           43%                                       75%                                 41%   75%   32%   56%   55%   72%
  Abnormal waist circumference   56%                                       90%                                 55%   90%   49%   85%   66%   82%
  Elevated blood pressure        55%                                       89%                                 55%   89%   45%   79%   63%   81%
  Decreased HDL cholesterol      52%                                       87%                                 51%   87%   40%   73%   62%   78%
  Elevated triglycerides         50%                                       85%                                 49%   85%   39%   70%   57%   76%
  Elevated fasting glucose       53%                                       88%                                 53%   88%   42%   76%   59%   76%

**Notes:** Frequencies of *GSTM1* null, *GSTT1* null, and *SOD2* Val/Val genotypes were fixed as 50.0%, 44.2%, and 73.4%, respectively, and those of overweight, MetS, abnormal waist circumference, elevated blood pressure, decreased HDL cholesterol, elevated triglycerides, and elevated fasting glucose were fixed as 47%, 22%, 55%, 41%, 34%, 31%, and 37%, respectively.

**Abbreviations:** MetS, metabolic syndrome; HDL, high density lipoprotein; *GST*, glutathione *S*-transferase; *SOD2*, superoxide dismutase 2; OR, odds ratio.

###### 

Demographic and clinical characteristics according to the *GSTM1* genotypes in smokers and nonsmokers among patients with schizophrenia

                                                                     Smokers (n=78)   Nonsmokers (n=76)                                      
  ------------------------------------------------------------------ ---------------- ------------------- ------- ------------- ------------ -------
  Number[b](#tfn48-ndt-9-1683){ref-type="table-fn"}                  42 (53.8%)       36 (46.2%)          --      35 (46.1%)    41 (53.9%)   --
  Age (years)                                                        45.5±13.8        52.7±15.3           0.033   49.9±15.7     53.2±15.7    0.371
  Male[c](#tfn49-ndt-9-1683){ref-type="table-fn"}                    29 (69.0%)       27 (75.0%)          0.620   12 (34.3%)    12 (29.3%)   0.805
  Height (cm)                                                        163.9±8.4        164.1±8.75          0.893   159.3±7.9     159.3±7.6    0.969
  Weight (kg)                                                        66.8±15.5        67.7±13.8           0.796   65.3±11.8     61.0±12.1    0.121
  BMI (kg/m^2^)                                                      24.7±4.3         25.0±3.86           0.751   25.7±4.0      24.0±4.1     0.071
  Overweight[c](#tfn49-ndt-9-1683){ref-type="table-fn"}              14 (33.3%)       18 (50.0%)          0.169   20 (57.1%)    20 (48.8%)   0.498
  Metabolic syndrome[c](#tfn49-ndt-9-1683){ref-type="table-fn"}      11 (26.2%)       12 (33.3%)          0.619   5 (14.3%)     6 (14.6%)    1.000
  Waist circumference (cm)                                           87.1±13.6        87.1±11.1           0.985   87.7±11.0     83.0±11.3    0.076
  Systolic blood pressure (mmHg)                                     122.3±13.5       127.3±15.7          0.132   123.8±15.8    130.2±19.8   0.131
  Diastolic blood pressure (mmHg)                                    75.6±11.2        77.0±11.4           0.582   76.3±9.4      78.4±15.0    0.481
  High-density lipoprotein (mg/dL)                                   53.5±15.8        45.8±13.6           0.026   54.5±14.6     54.2±13.1    0.931
  Triglycerides (mg/dL)                                              156.7±105.6      172.2±205.0         0.670   145.1±134.9   124.0±93.2   0.426
  Fasting blood glucose (mg/dL)                                      97.2±21.6        106.3±34.9          0.164   109.8±48.6    100.3±19.0   0.252
  Outpatients[c](#tfn49-ndt-9-1683){ref-type="table-fn"}             29 (69.0%)       23 (63.9%)          0.640   21 (60.0%)    20 (48.8%)   0.363
  Treatment with AAP(s)[c](#tfn49-ndt-9-1683){ref-type="table-fn"}   30 (71.4%)       31 (86.1%)          0.170   24 (68.6%)    27 (65.9%)   1.000

**Notes:** Data expressed as the mean ± standard deviation

*P*-values were determined by Student's *t*-test or Fisher's exact test

values in parentheses indicate the percentages in smokers and nonsmokers, respectively

values in parentheses indicate the percentages among the subjects with each genotype.

**Abbreviations:** AAP(s), atypical antipsychotics except for aripiprazole; BMI, body mass index; *GST*, glutathione *S*-transferase.

The authors wish to thank all of the study participants. This work was supported by grants from the Japan Research Foundation for Clinical Pharmacology, the Research Group for Schizophrenia, and KAKENHI (23510348, 24590652, 25860117), and in part by a grant from the Smoking Research Foundation. The authors thank Yoshiyuki Tsuda and Motoki Imamura for their help with the DNA extraction and genotyping polymorphisms.

**Disclosure**

The authors report no conflicts of interest in this work.

![Genotyping of *GSTM1* and *GSTT1* using polymerase chain reaction. M, 100 bp DNA marker. Lane 1: *GSTT1* present (460 bp) genotype and β-globin (260 bp). Lane 2: *GSTT1* null genotype and β-globin (260 bp). Lane 3: *GSTM1* present genotype (230 bp) and β-globin as an internal control (260 bp). Lane 4: *GSTM1* null genotype and β-globin (260 bp). Present: subjects with homozygous or heterozygous wild-type allele(s). Null: subjects with homozygous deleted alleles.](ndt-9-1683Fig1){#f1-ndt-9-1683}

###### 

Demographic and clinical characteristics of study subjects

                                     Schizophrenia patients (n=154)   Controls (n=203)   *P*
  ---------------------------------- -------------------------------- ------------------ ----------
  Age (years)                        50.2±15.3                        52.4±9.0           0.124
  Male                               80 (51.9%)                       117 (57.6%)        0.334
  Height (cm)                        161.7±8.4                        162.9±8.9          0.205
  Weight (kg)                        65.1±13.6                        61.7±10.9          0.011
  BMI (kg/m^2^)                      24.8±4.1                         23.2±3.2           \<0.0001
  Overweight                         72 (46.8%)                       49 (24.1%)         \<0.0001
  Metabolic syndrome                 34 (22.1%)                       15 (7.4%)          \<0.0001
  Waist circumference (cm)           86.2±11.9                        82.8±8.1           0.003
  Systolic blood pressure (mmHg)     125.9±16.5                       117.2±16.2         \<0.0001
  Diastolic blood pressure (mmHg)    76.8±12.0                        72.9±11.0          0.001
  High-density lipoprotein (mg/dL)   52.1±14.6                        65.6±17.2          \<0.0001
  Triglycerides (mg/dL)              149.0±138.7                      121.0±88.1         0.029
  Fasting glucose (mg/dL)            103.0±32.4                       96.3±20.1          0.070
  Smoker                             78 (50.6%)                       43 (21.2%)         \<0.0001
  Outpatient                         93 (60.4%)                       --                 --
  Treatment with AAP(s)              112 (72.7%)                      --                 --

**Note:** Data expressed as the mean ± standard deviation or number (%).

**Abbreviations:** AAP(s), atypical antipsychotic(s) except for aripiprazole; BMI, body mass index.

###### 

Associations between genotypes and risk of metabolic abnormalities in patients with schizophrenia and age/sex-matched controls

  Parameter                      Genotype              Schizophrenia (n= 154)   Controls (n=203)                                                                                  
  ------------------------------ --------------------- ------------------------ ------------------ ------------------------- ------- ------------ ------- ----------------------- -------
  Overweight                     *GSTM1*                                                                                                                                          
                                  Present              34 (44.2%)               0.628              1                                 26 (25.0%)   0.870   1                       
                                  Null                 38 (49.4%)                                  9.427 (0.763--116.452)    0.080   23 (23.2%)           0.887 (0.461--1.706)    0.719
                                 *GSTT1*                                                                                                                                          
                                  Present              40 (46.5%)               1.000              1                                 24 (23.1%)   0.745   1                       
                                  Null                 32 (47.1%)                                  0.209 (0.016--2.727)      0.232   25 (25.3%)           1.135 (0.588--2.189)    0.706
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   17 (41.5%)               0.469              1                                 15 (30.0%)   0.261   1                       
                                  Val/Val              55 (48.7%)                                  2.215 (0.137--35.922)     0.576   34 (22.2%)           0.677 (0.329--1.396)    0.291
  MetS                           *GSTM1*                                                                                                                                          
                                  Present              16 (20.8%)               0.846              1                                 9 (8.7%)     0.595   1                       
                                  Null                 18 (23.4%)                                  1.539 (0.071--33.414)     0.784   6 (6.1%)             0.720 (0.237--2.186)    0.562
                                 *GSTT1*                                                                                                                                          
                                  Present              17 (19.8%)               0.442              1                                 5 (4.8%)     0.184   1                       
                                  Null                 17 (25.0%)                                  2.496 (0.112--55.817)     0.564   10 (10.1%)           1.795 (0.572--5.630)    0.316
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   10 (24.4%)               0.666              1                                 4 (8.0%)     0.765   1                       
                                  Val/Val              24 (21.2%)                                  2.372 (0.069--81.138)     0.632   11 (7.2%)            0.909 (0.264--3.126)    0.879
  Abnormal waist circumference   *GSTM1*                                                                                                                                          
                                  Present              44 (57.1%)               0.746              1                                 29 (27.9%)   0.447   1                       
                                  Null                 41 (53.2%)                                  7.889 (0.717--86.793)     0.091   33 (33.3%)           1.445 (0.761--2.742)    0.261
                                 *GSTT1*                                                                                                                                          
                                  Present              46 (53.5%)               0.744              1                                 29 (27.9%)   0.447   1                       
                                  Null                 39 (57.4%)                                  0.814 (0.083--7.965)      0.860   33 (33.3%)           1.181 (0.621--2.247)    0.613
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   20 (48.8%)               0.363              1                                 16 (32.0%)   0.860   1                       
                                  Val/Val              65 (57.5%)                                  2.216 (0.224--21.960)     0.497   46 (30.1%)           0.900 (0.431--1.880)    0.778
  Elevated blood pressure        *GSTM1*                                                                                                                                          
                                  Present              29 (37.7%)               0.414              1                                 31 (29.8%)   0.879   1                       
                                  Null                 35 (45.5%)                                  8.366 (0.758--92.350)     0.083   31 (31.3%)           1.073 (0.583--1.975)    0.821
                                 *GSTT1*                                                                                                                                          
                                  Present              33 (38.4%)               0.412              1                                 36 (34.6%)   0.224   1                       
                                  Null                 31 (45.6%)                                  1.962 (0.183--21.046)     0.578   26 (26.3%)           0.627 (0.338--1.165)    0.140
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   22 (53.7%)               0.095              1                                 15 (30.0%)   1.000   1                       
                                  Val/Val              42 (37.2%)                                  0.569 (0.044--7.420)      0.667   47 (30.7%)           1.033 (0.508--2.102)    0.928
  Decreased HDL cholesterol      *GSTM1*                                                                                                                                          
                                  Present              22 (28.6%)               0.233              1                                 4 (3.8%)     0.530   1                       
                                  Null                 30 (39.0%)                                  11.428 (0.874--149.423)   0.063   6 (6.1%)             1.685 (0.446--6.367)    0.441
                                 *GSTT1*                                                                                                                                          
                                  Present              32 (37.2%)               0.391              1                                 5 (4.8%)     1.000   1                       
                                  Null                 20 (29.4%)                                  1.392 (0.119--16.261)     0.792   5 (5.1%)             1.115 (0.299--4.158)    0.872
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   11 (26.8%)               0.337              1                                 1 (2.0%)     0.456   1                       
                                  Val/Val              41 (36.3%)                                  5.936 (0.453--77.715)     0.175   9 (5.9%)             2.848 (0.346--23.430)   0.330
  Elevated triglycerides         *GSTM1*                                                                                                                                          
                                  Present              25 (32.5%)               0.862              1                                 25 (24.0%)   1.000   1                       
                                  Null                 23 (29.9%)                                  1.181 (0.084--16.568)     0.902   23 (23.2%)           0.948 (0.488--1.843)    0.875
                                 *GSTT1*                                                                                                                                          
                                  Present              25 (29.1%)               0.600              1                                 22 (21.2%)   0.413   1                       
                                  Null                 23 (33.8%)                                  4.903 (0.381--63.157)     0.223   26 (26.3%)           1.458 (0.745--2.853)    0.271
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   12 (29.3%)               0.845              1                                 11 (22.0%)   0.849   1                       
                                  Val/Val              36 (31.9%)                                  0.949 (0.059--15.254)     0.971   37 (24.2%)           1.080 (0.496--2.354)    0.846
  Elevated fasting glucose       *GSTM1*                                                                                                                                          
                                  Present              27 (35.1%)               0.739              1                                 26 (25.0%)   0.873   1                       
                                  Null                 30 (39.0%)                                  3.590 (0.276--46.722)     0.329   26 (26.3%)           1.093 (0.550--2.172)    0.799
                                 *GSTT1*                                                                                                                                          
                                  Present              33 (38.4%)               0.739              1                                 24 (23.1%)   0.424   1                       
                                  Null                 24 (35.3%)                                  5.007 (0.421--59.492)     0.202   28 (28.3%)           1.513 (0.754--3.033)    0.244
                                 *SOD2* Vall6Ala                                                                                                                                  
                                  Ala/Ala or Ala/Val   16 (39.0%)               0.851              1                                 11 (22.0%)   0.578   1                       
                                  Val/Val              41 (36.3%)                                  1.285 (0.088--18.657)     0.854   41 (26.8%)           1.224 (0.544--2.752)    0.625

**Notes:**

Frequency and percentage indicate those of the metabolic abnormalities for each genotype

Fisher's exact test

OR (95% CI) and *P*-values were calculated by logistic regression analysis that included all genotypes, patient-related categorical factors (ie, sex, smoking status, treatment with or without atypical antipsychotics, or inpatient/outpatient status), interactions between genotypes, interactions between genotypes and patient-related factors as fixed effects, and age was included as a random effect.

**Abbreviations:** CI, confidence interval; *GST*, glutathione S-transferase; HDL, high-density lipoprotein; MetS, metabolic syndrome; *SOD2*, superoxide dismutase 2; OR, odds ratio.

###### 

Association between *GSTM1* genotype and risk of metabolic abnormalities in smokers and nonsmokers among patients with schizophrenia

  Parameter                      *GSTM1* genotype   Smokers (n=78)   Nonsmokers (n=76)                                                                        
  ------------------------------ ------------------ ---------------- ---------------------- ------- ------------ ------------ ----------------------- ------- --
  Overweight                     Present            14 (33.3%)       0.169                  1                    20 (57.1%)   0.498                   1       
  Null                           18 (50.0%)                          3.202 (1.081--9.480)   0.036   20 (48.8%)                0.610 (0.225--1.652)    0.331   
  MetS                           Present            11 (26.2%)       0.619                  1                    5 (14.3%)    1.000                   1       
  Null                           12 (33.3%)                          1.629 (0.550--4.828)   0.378   6 (14.6%)                 0.797 (0.180--3.534)    0.765   
  Abnormal waist circumference   Present            21 (50.0%)       0.367                  1                    23 (65.7%)   0.109                   1       
  Null                           22 (61.1%)                          2.014 (0.750--5.412)   0.165   19 (46.3%)                0.336 (0.1 17--0.968)   0.043   
  Elevated blood pressure        Present            16 (38.1%)       0.493                  1                    13 (37.1%)   0.642                   1       
  Null                           17 (47.2%)                          1.630 (0.579--4.590)   0.355   18 (43.9%)                1.182 (0.428--3.263)    0.747   
  Decreased HDL cholesterol      Present            11 (26.2%)       0.062                  1                    11 (31.4%)   1.000                   1       
  Null                           17 (47.2%)                          3.151 (1.062--9.350)   0.039   13 (31.7%)                0.852 (0.278--2.609)    0.779   
  Elevated triglycerides         Present            15 (35.7%)       0.810                  1                    10 (28.6%)   1.000                   1       
  Null                           11 (30.6%)                          1.003 (0.331--3.036)   0.996   12 (29.3%)                1.144 (0.392--3.342)    0.806   
  Elevated fasting glucose       Present            11 (26.2%)       0.159                  1                    16 (45.7%)   0.486                   1       
  Null                           15 (41.7%)                          1.956 (0.612--6.253)   0.258   15 (36.6%)                0.684 (0.248--1.883)    0.462   

**Notes:**

Frequency and percentage indicate those of the metabolic abnormalities for each genotype

Fisher's exact test

OR (95% CI) and P-values were calculated by logistic regression analysis that included the *GSTMI, GSTTI*, and *SOD2* genotypes, patient-related categorical factors (ie, sex, treatment with or without atypical antipsychotics, or inpatient/outpatient status) as fixed effects, and age as a random effect.

**Abbreviations:** CI, confidence interval; *GST*, glutathione S-transferase; HDL, high-density lipoprotein; MetS, metabolic syndrome; OR, odds ratio.

###### 

Frequency distribution of combinations of *GSTM1* and *GSTT1* genotypes in schizophrenic subjects with metabolic abnormalities

  Parameter                      *GSTM1* genotype   *GSTT1* genotype   Frequency (%)[a](#tfn11-ndt-9-1683){ref-type="table-fn"}   *P*[b](#tfn12-ndt-9-1683){ref-type="table-fn"}   OR (95% CI)[c](#tfn13-ndt-9-1683){ref-type="table-fn"}   *P*[c](#tfn13-ndt-9-1683){ref-type="table-fn"}
  ------------------------------ ------------------ ------------------ ---------------------------------------------------------- ------------------------------------------------ -------------------------------------------------------- ------------------------------------------------
  Overweight                     Present            Present            20 (40.8%)                                                 0.660                                            1                                                        
  Null                           Present            20 (54.1%)                                                                    2.032 (0.824--5.012)                             0.124                                                    
  Present                        Null               14 (50.0%)                                                                    1.789 (0.656--4.876)                             0.256                                                    
  Null                           Null               18 (45.0%)                                                                    1.475 (0.600--3.626)                             0.398                                                    
  MetS                           Present            Present            7 (14.3%)                                                  0.252                                            1                                                        
  Null                           Present            10 (27.0%)                                                                    2.297 (0.751--7.028)                             0.145                                                    
  Present                        Null               9 (32.1%)                                                                     2.778 (0.843--9.147)                             0.093                                                    
  Null                           Null               8 (20.0%)                                                                     1.830 (0.568--5.898)                             0.311                                                    
  Abnormal waist circumference   Present            Present            25 (51.0%)                                                 0.449                                            1                                                        
  Null                           Present            21 (56.8%)                                                                    1.225 (0.512--2.929)                             0.649                                                    
  Present                        Null               19 (67.9%)                                                                    1.997 (0.730--5.464)                             0.178                                                    
  Null                           Null               20 (50.0%)                                                                    1.024 (0.432--2.429)                             0.957                                                    
  Elevated blood pressure        Present            Present            18 (36.7%)                                                 0.651                                            1                                                        
  Null                           Present            15 (40.5%)                                                                    1.290 (0.517--3.221)                             0.586                                                    
  Present                        Null               11 (39.3%)                                                                    1.252 (0.449--3.496)                             0.668                                                    
  Null                           Null               20 (50.0%)                                                                    1.825 (0.735--4.533)                             0.195                                                    
  Decreased HDL cholesterol      Present            Present            12 (24.5%)                                                 0.021                                            1                                                        
  Null                           Present            20 (54.1%)                                                                    3.599 (1.409--9.193)                             0.007                                                    
  Present                        Null               10 (37.5%)                                                                    1.535 (0.533--4.419)                             0.427                                                    
  Null                           Null               10 (25.0%)                                                                    0.919 (0.337--2.505)                             0.869                                                    
  Elevated triglycerides         Present            Present            12 (24.5%)                                                 0.180                                            1                                                        
  Null                           Present            13 (35.1%)                                                                    1.882 (0.702--5.043)                             0.209                                                    
  Present                        Null               13 (46.4%)                                                                    2.813 (0.972--8.140)                             0.057                                                    
  Null                           Null               10 (25.0%)                                                                    1.425 (0.507--4.004)                             0.501                                                    
  Elevated fasting glucose       Present            Present            17 (34.7%)                                                 0.845                                            1                                                        
  Null                           Present            16 (43.2%)                                                                    1.482 (0.580--3.783)                             0.411                                                    
  Present                        Null               10 (35.7%)                                                                    1.399 (0.479--4.088)                             0.540                                                    
  Null                           Null               14 (35.0%)                                                                    1.036 (0.399--2.688)                             0.942                                                    

**Notes:**

Frequency and percentage indicate those of the metabolic abnormalities for each genotype

Fisher's exact test

OR (95% CI) and *P*-values were calculated by logistic regression analysis that included combinations of the *GSTM1* and *GSTT1* genotypes, *SOD2* genotypes, patient-related categorical factors (ie, sex, treatment with or without atypical antipsychotics, or inpatient/outpatient status) as fixed effects, and age as a random effect.

**Abbreviations:** CI, confidence interval; *GST*, glutathione *S*-transferase; HDL, high density lipoprotein; MetS, metabolic syndrome; OR, odds ratio; *SOD2*, superoxide dismutase 2.

###### 

Association of *GSTM1* genotype with risk of metabolic abnormalities in smokers and nonsmokers and association of combinations of *GSTM1* and *GSTT1* genotypes among age/sex-matched controls

  Subjects                       Parameter                   Genotype                          Frequency (%)[a](#tfn15-ndt-9-1683){ref-type="table-fn"}   *P*[b](#tfn16-ndt-9-1683){ref-type="table-fn"}   OR (95% CI)[c](#tfn17-ndt-9-1683){ref-type="table-fn"}   *P*[c](#tfn17-ndt-9-1683){ref-type="table-fn"}
  ------------------------------ --------------------------- --------------------------------- ---------------------------------------------------------- ------------------------------------------------ -------------------------------------------------------- ------------------------------------------------
  Smokers (n=43)                 Overweight                  *GSTM1* present                   5 (23.8%)                                                  0.457                                            1                                                        
  *GSTM1* null                   3 (13.6%)                                                     0.566 (0.106--3.036)                                       0.507                                                                                                     
  Abnormal waist circumference   *GSTM1* present             5 (23.8%)                         1.000                                                      1                                                                                                         
  *GSTM1* null                   5 (22.7%)                                                     1.568 (0.275--8.941)                                       0.613                                                                                                     
  Decreased HDL cholesterol      *GSTM1* present             1 (4.8%)                          0.607                                                      1                                                                                                         
  *GSTM1* null                   3 (13.6%)                                                     2.782 (0.228--33.873)                                      0.422                                                                                                     
  Nonsmokers (n=160)             Overweight                  *GSTM1* present                   21 (25.3%)                                                 1.000                                            1                                                        
  *GSTM1* null                   20 (26.0%)                                                    1.010 (0.490--2.081)                                       0.979                                                                                                     
  Abnormal waist circumference   *GSTM1* present             24 (28.9%)                        0.399                                                      1                                                                                                         
  *GSTM1* null                   28 (36.4%)                                                    1.540 (0.755--3.140)                                       0.235                                                                                                     
  Decreased HDL cholesterol      *GSTM1* present             3 (3.6%)                          1.000                                                      1                                                                                                         
  *GSTM1* null                   3 (3.9%)                                                      1.147 (0.220--5.981)                                       0.871                                                                                                     
  All (n=203)                    Decreased HDL cholesterol   *GSTM1* present/*GSTT1* present   2 (4.0%)                                                   0.919                                            1                                                        
  *GSTM1* null/*GSTT1* present   3 (5.6%)                                                      1.230 (0.190--7.962)                                       0.828                                                                                                     
  *GSTM1* present/*GSTT1* null   2 (3.7%)                                                      0.773 (0.100--5.968)                                       0.805                                                                                                     
  *GSTM1* null/*GSTT1* null      3 (6.7%)                                                      1.763 (0.273--11.379)                                      0.551                                                                                                     

**Notes:**

Frequency and percentage indicate those of the metabolic abnormalities for each genotype

Fisher's exact test

OR (95% CI) and *P*-values were calculated by logistic regression analysis that included the *GSTM1* and *GSTT1* genotypes (or combinations of the *GSTM1* and *GSTT1* genotypes), *SOD2* genotypes, and sex as fixed effects, and age as a random effect.

**Abbreviations:** CI, confidence interval; *GST*, glutathione *S*-transferase; HDL, high-density lipoprotein; OR, odds ratio; *SOD2*, superoxide dismutase 2.
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